Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC
This clinical study was a first-in-human, phase 1B, single-center, single-arm, open-label, dose escalation and expansion trial that aimed to determine the safety, tolerability and efficacy of BEBT-109 in patients with locally advanced or metastatic NSCLC harboring EGFR exon20ins mutations who had received at least one line of previous treatment.
NSCLC
DRUG: BEBT-109
DLT, Defined as one of adverse events defined by NCI CTCAE V5.0 from the first day to the 28th day of the treatment period., 2 years|MTD, If only 1 of 3 participants in a dose group has DLT, 3 additional subjects in this group will be tested at the same dose level; If no participants developed DLT, the next dose study was conducted; If 2 of the first 3 participants developed DLT or 2 of 6 participants developed DLT, the previous dose of the dose was the maximum tolerated dose (MTD)., 2 years
ORR, Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects, 2 years|DCR, Defined as the proportion of subjects with complete remission (CR), partial remission (PR) and stable disease (SD) to the total subjects, 2 years
This clinical study was a first-in-human, phase 1B, single-center, single-arm, open-label, dose escalation and expansion trial that aimed to determine the safety, tolerability and efficacy of BEBT-109 in patients with locally advanced or metastatic NSCLC harboring EGFR exon20ins mutations who had received at least one line of previous treatment.